This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Glisson, B. S. Articles by Forastiere, A. A. Search for Related Content PubMed PubMed Citation Articles by Glisson, B. S. Articles by Forastiere, A. A. Social Bookmarking                            What's this?

Phase II Trial of Docetaxel and Cisplatin Combination Chemotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

From the University of Texas M.D. Anderson Cancer Center, Houston, TX; Vanderbilt University, Nashville, TN; Carolina Health Care, Blumenthal Cancer Center, Charlotte, NC; and Johns Hopkins University, Baltimore, MD.

Address reprint requests to Bonnie S. Glisson, MD, Box 432, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030-4008; email: bglisson{at}mdanderson.org

PURPOSE: To assess the antitumor activity and toxicity of docetaxel plus cisplatin chemotherapy in patients with recurrent or incurable squamous cell carcinoma of the head and neck (SCCHN).

PATIENTS AND METHODS: Patients with recurrent or incurable SCCHN were eligible if they were chemotherapy naive or if they had received one prior regimen as neoadjuvant or concurrent treatment with radiation. Patients who had received chemotherapy for recurrence or prior taxanes were ineligible. Patients received docetaxel 75 mg/m² and cisplatin 75 mg/m² on day 1; cycles were repeated every 21 days.

RESULTS: Toxic effects and length of survival were assessable in 36 patients and tumor response was assessable in 32, for whom the overall response rate was 40% (13 of 32) (6% complete response and 34% partial response). Median time to response was 5 weeks, and median duration was 4.9 months. In the intent to treat population (n = 36), median time to disease progression was 4 months. Median survival (n = 36) was 9.6 months, and the 12-month survival rate was 27%. Grade 4 neutropenia was observed in 71% of patients. Two patients (6%) experienced serious fever during grade 4 neutropenia (without documented infection) that required intravenous antibiotics, and an additional four patients had grade 3 infection. Other severe (grades 3 and 4) toxic effects were asthenia (25%), nausea (11%), fever (8%), vomiting (8%), severe hypersensitivity reactions (8%), and diarrhea (8%). Severe stomatitis (grade 3) occurred in only one patient.

CONCLUSION: Docetaxel plus cisplatin is an effective regimen with an acceptable safety profile for palliation of recurrent SCCHN. Relative to the standard regimen of cisplatin/fluorouracil, this regimen may offer higher tumor response and survival rates with short outpatient administration and a lower incidence of severe mucosal toxicity.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. FOUNTZILAS, A. BAMIAS, A. KALOGERA-FOUNTZILA, G. KARAYANNOPOULOU, M. BOBOS, E. ATHANASSIOU, K. T. KALOGERAS, C. TOLIS, P. TSEKERIS, P. PAPAKOSTAS, et al. Induction Chemotherapy with Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy in Patients with Inoperable Non-nasopharyngeal Carcinoma of the Head and Neck Anticancer Res, February 1, 2009; 29(2): 529 - 538. [Abstract] [Full Text] [PDF]

				T. J. Smith, J. Khatcheressian, G. H. Lyman, H. Ozer, J. O. Armitage, L. Balducci, C. L. Bennett, S. B. Cantor, J. Crawford, S. J. Cross, et al. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline J. Clin. Oncol., July 1, 2006; 24(19): 3187 - 3205. [Abstract] [Full Text] [PDF]

				A. D. Roth, R. Maibach, N. Fazio, C. Sessa, R. Stupp, R. Morant, R. Herrmann, M. M. Borner, A. Goldhirsch, and F. de Braud 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere(R))-cisplatin in advanced gastric carcinoma: a phase I-II trial Ann. Onc., May 1, 2004; 15(5): 759 - 764. [Abstract] [Full Text] [PDF]

				D. Schrijvers, C. Van Herpen, J. Kerger, E. Joosens, C. Van Laer, A. Awada, D. Van den Weyngaert, H. Nguyen, C. Le Bouder, J. A. Castelijns, et al. Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study Ann. Onc., April 1, 2004; 15(4): 638 - 645. [Abstract] [Full Text] [PDF]

				D. Soulieres, N. N. Senzer, E. E. Vokes, M. Hidalgo, S. S. Agarwala, and L. L. Siu Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck J. Clin. Oncol., January 1, 2004; 22(1): 77 - 85. [Abstract] [Full Text] [PDF]